REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
Bleichmar Fonti & Auld LLP issued a shareholder-solicitation notice naming Regeneron regarding a class action lawsuit alleging securities fraud tied to the Fianlimab-Libtayo Phase III trial. The complaint alleges the company misled investors before revealing the study did not achieve statistical significance, resulting in stock drops of 6.2% on April 29 and 9.8% on May 15.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.